Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Neutrophil activation cause of inflammation in canine liver disease
Liver disease is a major health issue in dogs.
Research links high ammonia levels to immune response and inflammation

The Royal (Dick) School of Veterinary Medicine and The Roslin Institute have discovered that high levels of ammonia in dogs with liver disease causes an unregulated immune response by activating neutrophils. The resultant inflammation seen in these cases then further decreases the dog’s overall health.

Inflammatory molecules and high levels of ammonia are commonly discovered in canine liver disease cases and, while treating the liver disease generally results in a decrease in both ammonia and inflammation levels, it has not been known until now what caused the associated inflammation.

Inflammation is a natural and often useful immune response when infection is present, but it is thought that when this response is activated inappropriately, that significant detriment can occur within the body.

Craig R. Breheny, lead scientist involved in the research, states: “Liver disease is a huge issue both in human and veterinary medicine. This study shows how the relationship between ammonia and the inflammatory response strengthens the dog’s role as a model of the human condition”.

Treatment for liver disease is often supportive and the aetiology is largely unknown.

By closely observing the precise activity of these neutrophils, the researchers hope to develop improved treatment and to prevent this unregulated immune response. Breheny concludes: “By understanding how the disease works, new therapies can be investigated to the benefit of both veterinary and human patients”.

 

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
BSAVA announces 12th Edition of the Small Animal Formulary

The BSAVA has published an updated edition of its Small Animal Formulary, which includes new drug monographs and emergency drug doses for rabbits, rodents, birds and reptiles.

One of BSAVA's most trusted and widely used clinical resources, this 12th edition of the manual also includes seven new client information leaflets and information on drugs used for the management of urinary incontinence.

Part A of the Formulary, Canine and Feline, sees Fergus Allerton return as Editor-in-Chief, while Part B: Exotic Pets was edited by Joanna Hedley. For more information, visit the BSAVA website.